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Despite the development of novel antibiotics active against Gram-positive bacteria, vancomycin generally
remains the first treatment, although rapidly achieving concentrations associated with maximal efficacy
provides an unresolved challenge. The objective of this study was to conduct a population pharmacokinetic
analysis of vancomycin in a large population of critically ill patients. This was a retrospective data collection
of 206 adult septic critically ill patients who were administered vancomycin as a loading dose followed by
continuous infusion. The concentration-versus-time data for vancomycin in serum was analyzed by a nonlinear
mixed-effects modeling approach using NONMEM. Monte Carlo simulations were performed using the final
covariate model. We found that the best population pharmacokinetic model consisted of a one-compartment
linear model with combined proportional and additive residual unknown variability. The volume of distribu-
tion of vancomycin (1.5 liters/kg) was described by total body weight and clearance (4.6 liters/h) by 24-hour
urinary creatinine clearance (CrCl), normalized to body surface area. Simulation data showed that a 35-mg/kg
loading dose was necessary to rapidly achieve vancomycin concentrations of 20 mg/liter. Daily vancomycin
requirements were dependent on CrCl, such that a patient with a CrCl of 100 ml/min/1.73 m2 would require
at least 35 mg/kg per day by continuous infusion to maintain target concentrations. In conclusion, we have
found that higher-than-recommended loading and daily doses of vancomycin seem to be necessary to rapidly
achieve therapeutic serum concentrations in these patients.
Infections in critically ill patients occur frequently and may
lead to the development of sepsis or septic shock. The mor-
bidity and mortality rates for sepsis and septic shock remain
unacceptably high, with septic shock still associated with a 35
to 65% in-hospital mortality rate (5, 9). A significant body of
work now describes the importance of early and appropriate
antibiotic therapy as the intervention likely to minimize ther-
apeutic failure (10, 17, 18).
Of significant concern for clinicians is the increasing preva-
lence of multidrug-resistant bacteria, particularly methicillin-
resistant Staphylococcus aureus (MRSA), which has been
found to be the causative pathogen in more than 10% of
infections resulting in septic shock (9). Furthermore, data from
the United States have reported that 25.8% of bacteremias are
due to MRSA (4), with mortality rates for MRSA bacteremia
in critically ill patients being reported as between 45 and 55%
(3, 13). Certainly, mortality rates for MRSA pneumonia in
critically ill patients may be even higher (12). While newer
agents are now available, vancomycin remains the standard of
care for treatment of MRSA infections in the intensive care
unit (ICU) (30).
Despite vancomycin being in ubiquitous use for over 50
years, dosing in specific populations, particularly the critically
ill, remains confused. Conventional dosing regimens of 500 mg
every 6 h or 1 g every 12 h have little evidence supporting their
efficacy (7), while data from the work of Moise-Broder et al.
(22) for MRSA pneumonia suggest that standard dosing ap-
proaches are unlikely to achieve the required pharmacody-
namic index of vancomycin exposure needed for optimal ac-
tivity. Pursuant to this, a consensus review in 2009 by the
American Society of Health System Pharmacists, the Infec-
tious Diseases Society of America, and the Society of Infec-
tious Disease Pharmacists (ASHP/IDSA/SDIP) recommended
more-aggressive vancomycin dosing to achieve the pharmaco-
dynamic index associated with efficacy (30).
Continuous infusion (CI) of vancomycin allows more rapid
achievement of therapeutic drug concentrations than does in-
termittent infusion and may optimize its bactericidal activity.
Recent publications recommend a loading dose of 15 mg/kg of
body weight followed by a daily dose of 30 mg/kg (33); how-
ever, data on the efficacy of this strategy in a septic population
are scarce.
In this respect, the aim of this study was to conduct a pop-
ulation pharmacokinetic (PK) analysis of vancomycin contin-
uous administration in a large cohort of critically ill patients, in
order to better inform dosing in this population and to reduce
the risks for subtherapeutic drug exposure.
MATERIALS AND METHODS
Patients and data collection. We reviewed all the medical charts of patients
with a diagnosis of sepsis (18) admitted to the Intensive Care Unit (ICU) at
Erasme Hospital (Brussels, Belgium) between January 2008 and December 2009,
to whom continuous infusion (CI) of vancomycin, either in monotherapy or
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combined with other antimicrobials, was administered. Patients meeting any of
the following criteria were excluded: (i) age less than 18 yrs; (ii) previous ad-
ministration of vancomycin by intermittent infusion (48 h from the onset of
CI); (iii) renal replacement therapy; (iv) duration of CI of vancomycin of 48 h;
and (v) pregnancy, burns, or cystic fibrosis (because of altered pharmacokinetics,
independent of sepsis). The study period was limited to the ICU stay. Ethical
approval to conduct the study was granted by the local ethics committee.
For all study patients, data were collected in an institutional database. The
severity of illness of each patient was characterized using the Acute Physiology
and Chronic Health Evaluation (APACHE) II (16) and sepsis organ failure
assessment (SOFA) (32) scores determined on the first day of antibiotic treat-
ment. Urinary creatinine clearance (CrCl) was collected as a routine procedure
in all of the patients, calculated daily, and normalized to body surface area
(BSA). Treatment of patients with catecholamines or mechanical ventilation was
also recorded, as was length of ICU and hospital stay, overall mortality, and
cause of death.
Vancomycin treatment. Administration of vancomycin (Vancocin; Eli Lilly,
Indianapolis, IN) was by continuous infusion in accordance with local guidelines
and often empirical in the setting of presumed or documented Gram-positive
hospital- or ICU-acquired infections, especially when MRSA or other resistant
Gram-positive bacteria (i.e., Staphylococcus epidermidis or ampicillin-resistant
Enterococcus) were suspected. Continuous infusion is the preferred method of
administration in the unit where the data collection occurred because we believe
dose adjustment to achieve therapeutic concentrations to be easier with contin-
uous infusion than with intermittent infusion. Previous clinical outcome studies
have shown equivalent outcomes for vancomycin administered by either ap-
proach (33). In this study, the choice of antibiotic regimen was at the discretion
of the clinician; published recommendations (15-mg/kg loading dose followed by
30-mg/kg daily dose calculated on the total body weight [TBW]) (33), with doses
rounded off to 125 mg, were used in some patients. In others, local simplified
recommendations were used, consisting of a 750-mg (if TBW was 70 kg) or a
1,000-mg (if TBW was 70 kg) loading dose diluted in 100 ml of 5% dextrose in
water and administered over 30 min, followed by a 2,000-mg (if TBW was 70
kg) or a 3,000-mg (if TBW was 70 kg) daily dose of vancomycin, diluted in 250
ml of 5% dextrose in water and infused over 24 h in the case of normal renal
function. In the case of renal failure, the loading dose was unchanged but the
daily dose was adapted to the renal clearance. The aim of this regimen was to
provide serum drug concentrations between 20 and 30 mg/liter (28). Where
concentrations were less than 20 mg/liter, a loading dose of 500 mg was used and
an increase of 500 to 1,000 mg per day of total dose was made. In patients where
concentrations were greater than 30 mg/liter, CI was discontinued for 4 h and the
total dose was reduced by 500 to 1,000 mg per day.
Vancomycin assay. Concentrations of vancomycin in serum were determined
by fluorescence polarization immunoassay (TDx; Diagnostic Division, Abbott
Laboratories, Irving, TX). The assay limits and intraday and between-day coef-
ficients of variation for vancomycin were 0.6 mg/ml and 0.6%, respectively. The
linearity (r2) of the assay was 0.999.
Blood samples (5 ml) for drug assays were taken every day at 8 a.m. and sent
immediately to the central laboratory. As the aim was to examine the “pseudo-
steady-state” phase of the drug regimen, at least 16 h from the onset of CI was
allowed before sampling. We use the term “pseudo-steady-state” because
whether steady state is ever achieved in ICU patients with sepsis is debatable.
The exact sampling time was recorded by the nursing or medical staff in a
computerized ICU system.
Pharmacokinetic and statistical analysis. The concentration-versus-time data
for vancomycin in serum were analyzed by a nonlinear mixed-effects modeling
approach (2) using NONMEM (version 6.1; GloboMax LLC, Hanover, MD)
with double precision with the Compaq VISUAL FORTRAN compiler. The
NONMEM runs were executed using Wings for NONMEM (WFN 6.1.3). Data
were analyzed using the first-order conditional estimation method with the In-
teraction program.
For the population pharmacokinetic (PK) analysis, the serum vancomycin
concentrations were fitted to one-, two-, or three-compartment linear models
using subroutines from the NONMEM library (2). The concentration-time pro-
file can be described by equation 1:
Yij fiji, xij  eεlij ε2ij (1)
where yij is the jth observed concentration at time points xij for the ith subject.
Also, i represents the fixed-effects parameter of the structural model to be
estimated. fij is the function for the prediction of the jth response for the ith
subject. Finally, εij designates the jth measurement error for the ith subject. In
other words, εij is the difference of the observed concentration from the predicted
concentration. It is assumed to be independent and identically distributed with a
normal distribution around the mean zero and variance 2.
Between-subject variability. Between-subject variability was modeled using an
exponential variability model (equation 2):
i   ei (2)
where i is the value of the parameter for the ith subject,  is the typical value of
the parameter in the population, and finally i is a random vector with normal
distribution, zero mean, and variance-covariance matrix of between-subject vari-
ability  to be estimated.
Model diagnostics. To assess model validity, statistical comparison of nested
models was undertaken in NONMEM based on a 	2 test of the difference in the
objective function. A decrease in the objective function of 3.84 units (P  0.05)
was considered significant. Goodness of fit was evaluated by visual inspection of
diagnostic scatter plots, including observed and predicted concentrations versus
time, weighted residual versus time, and residual versus predicted concentra-
tions.
Bootstrap. A nonparametric bootstrap method (23) (n 
 1,000) was used to
study the uncertainty of all pharmacokinetic parameter estimates in the final
base model. From the bootstrap empirical posterior distribution, we have been
able to obtain the 95% confidence interval (2.5 to 97.5% percentile) for the
parameters, as described previously (21).
Covariate screening. The covariates analyzed were age, TBW, creatinine clear-
ance estimated from urinary 24-hour collection, gender, SOFA score, and body
mass index. Possible covariates were added in a stepwise fashion into the model.
Covariates were considered for inclusion in the model if they were biologically
plausible and there was improvement of the base model, i.e., decrease in objec-
tive function (at least 3.84 units), decrease in the unexplained between-subject
variability of the parameter, or decrease in residual unexplained variability.
Dosing simulations. Three sets of Monte Carlo dose simulations were under-
taken.
First, the effect of an initial TBW-based loading dose was simulated using
doses of 5 mg/kg (administered over 60 min), 15 mg/kg (administered over 60
min), 20 mg/kg (administered over 90 min), 25 mg/kg (administered over
120 min), 30 mg/kg (administered over 180 min), 35 mg/kg (administered over
180 min), and 40 mg/kg (administered over 180 min). The different durations of
infusion were chosen based on local clinical practice. The same daily continuous-
infusion dose was simulated for each of the loading doses (35 mg/kg for a patient
with a CrCl of 100 ml/min/1.73 m2).
Second, the effects of different creatinine clearances on vancomycin concen-
trations were simulated. The CrCls simulated were 50 ml/min/1.73 m2, 100
ml/min/1.73 m2, 150 ml/min/1.73 m2, 200 ml/min/1.73 m2, and 250 ml/min/1.73
m2. Each patient received a simulated loading dose of 35 mg/kg (over 180 min;
the duration was prolonged to minimize the likelihood of infusion-related tox-
icity), and the simulated continuous infusion dose was kept constant at 35 mg/kg
per day. The ability of each dosing regimen to achieve predefined pharmacody-
namic targets, a steady-state concentration (Css) of 20 mg/liter, was then
assessed. We also simulated the following CrCls to determine dose requirements
for continuous infusion after a 35-mg/kg loading dose: 20 ml/min/1.73 m2, 30
ml/min/1.73 m2, and 40 ml/min/1.73 m2.
Third, the effects of different weight-based dosing CI regimens on vancomycin
concentrations were simulated. The simulated patients each had a CrCl of 100
ml/min/1.73 m2 and received a 35-mg/kg loading dose over 180 min. The weight-
based regimens simulated were 20 mg/kg/day, 25 mg/kg/day, 30 mg/kg/day, 35
mg/kg/day, and 40 mg/kg/day. The ability of each dosing regimen to achieve
predefined pharmacodynamic targets, a steady-state concentration (Css) of 20
mg/liter, was then assessed.
RESULTS
The study included 206 patients, whose demographic details
are described in Table 1. Population pharmacokinetic model-
ing was performed using the concentration data from serum
samples. The best base model, using the model building crite-
ria, consisted of a one-compartment linear model with zero-
order input and combined proportional and additive residual
unknown variability. Other models could not be supported
because they did not result in an improvement in objective
function value or between-subject variability. Between-subject
variability was included for both clearance and volume of dis-
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tribution. The final objective function for the base model was
2,817.420.
The covariate that best described vancomycin volume of
distribution was TBW. The addition of this covariate reduced
the objective function by 6.129 (statistically significant change
is 3.84 units). The covariate that best described vancomycin
clearance was urinary CrCl normalized to 100 ml/min/1.73 m2.
The addition of this parameter improved the between-subject
variability for clearance by 10% and improved the goodness-
of-fit plots. The final population model for vancomycin was
represented by equations 3 and 4:
TVV 
 (1  TBW) (3)
TVCL 
 (2  CrCl/100) (4)
where TVV is the typical value of volume of distribution, TBW
is total body weight, and TVCL is the typical value of vanco-
mycin clearance. None of the other covariates statistically sig-
nificantly improved the model, and therefore, they could not
be included.
The values of the parameters for the final model are given in
Table 2 and include the 95% confidence intervals for the pa-
rameters computed from all bootstrap runs. The population
value for clearance of vancomycin was 4.6 liters/h (95% con-
fidence interval, 4.1 to 5.2), and that for volume of distribution
was 1.5 liters/kg (95% confidence interval, 1.3 to 1.7) (Table 2).
Figure 1 displays the goodness-of-fit plots for the final
model. Each of the patients contributed 2 to 3 samples, and of
the 579 samples included in the analysis, 10 samples had a
concentration greater than 2 standard deviations outside that
predicted by the model, which we considered acceptable given
the level of sickness severity and likely pharmacokinetic het-
erogeneity of the patient cohort. All subsequent dosing simu-
lations were then based on this model. All other visual predic-
tive checks were acceptable and confirmed the goodness of fit
of the model. The plots in Fig. 1 show that the final pharma-
cokinetic model describes the measured vancomycin concen-
trations adequately.
Dosing simulations. A loading dose of at least 35 mg/kg
TBW would have been necessary to rapidly achieve vancomy-
cin concentrations of 20 mg/liter within a few hours from the
onset of infusion (Fig. 2). A standard loading dose of 15 mg/kg
would have resulted in inadequate drug concentrations for the
first 24 h of therapy, despite an appropriate maintenance reg-
imen. The respective values for area under the concentration-
time curve from 0 to 24 h (AUC0–24) for these simulations
from 0 to 24 h were as follows: 5 mg/kg, 245 mg  h/liter; 15
mg/kg, 330 mg  h/liter; 20 mg/kg, 370 mg  h/liter; 25 mg/kg,
409 mg  h/liter; 30 mg/kg, 442 mg  h/liter; 35 mg/kg, 485
mg  h/liter; and 40 mg/kg, 532 mg  h/liter.
Figure 3 describes the impact of different values of creati-
nine clearance on vancomycin concentrations. In spite of an
effective loading dose of 35 mg/kg, a daily dose of 35 mg/kg
could not keep vancomycin concentrations within target levels
if the CrCl was 100 ml/min/1.73 m2. If patients had even higher
CrCls, a larger daily dose would have been necessary to main-
tain desired drug levels over the first 24 h of therapy. In the
case of an altered CrCl (50 ml/min/1.73 m2), a 35-mg/kg daily
dose could raise vancomycin levels to concentrations of 30
mg/liter within the first 24 to 48 of infusion (Fig. 3). To dem-
onstrate the importance of adequate maintenance doses for
maintaining therapeutic exposures, the respective AUCs for
these simulations of CrCl from 24 to 48 h were as follows: 50
ml/min, 811 mg  h/liter; 100 ml/min, 542 mg  h/liter; 150 ml/
min, 387 mg  h/liter; 200 ml/min, 293 mg  h/liter; and 250
ml/min, 232 mg  h/liter. When lower CrCl values were simu-
lated to determine doses to be infused over 24 h to maintain
vancomycin concentrations within the range of 20 to 25 mg/
liter, the simulations suggested the following requirements:
7 mg/kg over 24 h when the CrCl was 40 ml/min/1.73 m2, 10
mg/kg over 24 h when the CrCl was 30 ml/min/1.73 m2, and 14
mg/kg over 24 h when the CrCl was 40 ml/min/1.73 m2.
Figure 4 describes the vancomycin concentrations resulting
from various weight-based dosing infusions after an adequate
35-mg/kg loading dose to rapidly achieve a target concentra-
tion of 20 mg/liter. The simulations show that a dose of at least
35 mg/kg is required to maintain a therapeutic concentration
for a patient with a CrCl of 100 ml/min/1.73 m2. The respective
AUCs for these simulations of CrCl from 24 to 48 h were as
follows: 20 mg/kg, 362 mg  h/liter; 25 mg/kg, 419 mg  h/liter;
30 mg/kg, 475 mg  h/liter; 35 mg/kg, 532 mg  h/liter; and 40
mg/kg, 589 mg  h/liter.
DISCUSSION
This paper has provided a rational approach for optimized
vancomycin dosing by continuous infusion in critically ill pa-
TABLE 2. Bootstrap parameter final estimates of the final
covariate model
Parameter Mean
95% confidence interval
2.5
percentile
97.5
percentile
Fixed effects
Clearance (liters/h) 4.58 4.09 5.19
Volume of distribution (liters/kg) 1.53 1.31 1.71
Random effects: between-subject
variability, BSV
(% coefficient of variation)
Clearance 38.9 28.3 55.6
Volume of distribution 37.4 16.6 54.9
Random error
Residual unexplained variability
(% coefficient of variation)
19.9 14.5 24.6
SD (mg/liter) 2.4 1.3 3.0
TABLE 1. Demographic and clinical characteristics of patients
Variable Valuea
Age (yr) .....................................................................................58.1  14.8
Weight (kg)...............................................................................74.8  15.8
Height (cm) .............................................................................. 171  8
Body mass index (kg/m2) ........................................................25.9  5.4
Gender (% male)..................................................................... 61.6
Creatinine clearance (ml/min/1.73 m2) .................................90.7  60.4
APACHE II score.................................................................... 21 (16–27)
SOFA score .............................................................................. 7.6  4.2
a Data are described as mean  standard deviation or median (interquartile
range).
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tients and is the largest pharmacokinetic study on vancomycin
in this setting. Our results show that a loading dose based on
TBW is mandatory to rapidly achieve therapeutic concentra-
tions and suggest that a minimum loading dose of 35 mg/kg is
necessary to achieve target steady-state concentrations of 20
mg/liter or greater. To maintain this concentration, the dose to
be administered by continuous infusion can be accurately cal-
culated using data from CrCl. A daily dose of at least 35 mg/kg
would be necessary to maintain steady-state drug levels in the
therapeutic range. Such an approach to dosing will increase the
likelihood of achieving vancomycin concentrations associated
with improved antimicrobial activity and, potentially, positive
clinical outcomes (15, 22).
Achieving pharmacokinetic/pharmacodynamic targets is
likely to be very important for optimizing the clinical efficacy of
vancomycin. Consensus supports the view that the pharmaco-
kinetic-pharmacodynamic parameter best correlated with the
efficacy of vancomycin is the AUC0–24-to-MIC (AUC0–24/
MIC) ratio (8, 11, 29). In a retrospective study, Moise-Broder
et al. (22) evaluated the relationship between AUC0–24/MIC
ratio and clinical outcomes in patients with MRSA pneumonia.
The authors found that an AUC0–24/MIC ratio of 350 was
associated with clinical success and suggested an AUC0–24/
MIC ratio of 400 as a target predictive of optimal outcomes.
On the basis of the results of this study and the frequency with
which lung infections occur in critically ill patients, it has been
advocated that achieving this pharmacokinetic-pharmacody-
namic target of AUC0–24/MIC ratio of 400 should optimize
clinical benefit (6). Although AUC0–24 is not routinely moni-
tored in clinical practice, Jeffres et al. (14) have shown that
trough concentrations from intermittent dosing are correlated
with AUC and thus are regarded as an appropriate surrogate
measure for the AUC0–24 and as the most practical method to
monitor vancomycin dosing (26, 28). Some studies have suc-
cessfully described use of a nomogram to guide continuous-
infusion dosing (24).
We have shown that dosing to meet these targets needs to be
individualized according to the patient’s TBW and renal func-
tion. Data supporting the strong relationship between vanco-
mycin volume of distribution and TBW have been described in
various vancomycin pharmacokinetic studies, particularly in
obese patients (1). Data supporting the importance of renal
function on vancomycin clearance are also prominent (25).
Augmented renal clearance is common in hyperdynamic crit-
ically ill patients and may increase the risk for subtherapeutic
vancomycin exposure (27, 31). This population analysis ex-
tends upon these previous data and demonstrates how both
TBW and CrCl explain a significant amount of the pharmaco-
kinetic variability in critically ill patients.
Curiously, we did not observe an effect of the level of sick-
ness severity on volume of distribution, as has previously been
described for aminoglycosides (20). We believe that this may
be due to the dominant contribution of TBW as well as the
inherently larger volume of distribution of vancomycin (0.8 to
FIG. 1. Diagnostic plots for the final population pharmacokinetic covariate model. (Left) Observed concentrations versus the population
predicted concentrations (r2 
 0.07). (Right) Observed concentrations versus the individual predicted concentrations (r2 
 0.60). The nonlinear
regression line of fit is shown by the solid black line, and the line of x 
 y is the gray dotted line.
FIG. 2. The effect of loading dose on rapid attainment of target
vancomycin concentrations. Different weight-based doses are simu-
lated for a critically ill patient with a creatinine clearance of 100
ml/min/1.73 m2, followed by administration as a 35-mg/kg/day contin-
uous infusion.
FIG. 3. The effect of creatinine clearance on vancomycin concen-
trations administered by continuous infusion (35 mg/kg per day after
35-mg/kg loading dose).
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1.4 liters/kg [19]) compared with that of aminoglycosides (0.3
liter/kg [20]).
There are some limitations of our study. First, this modeling
approach utilized sparse samples, such that we were not able to
describe a two-compartment model, which mechanistically
would be more in keeping with the pharmacokinetics of van-
comycin. However, use of the program NONMEM for this
modeling process is widely recognized to be robust for such
analyses and the predictive performance of the model was
deemed sufficient. Second, this was an analysis of retrospective
data, which may have resulted in unforeseen errors in data
collection. We believe that this effect would be very minor
because of the use of continuous infusion of vancomycin and
sampling after a pharmacokinetic steady state had been
reached, in addition to the accuracy of the data collected on
CrCl. Third, the suggested approach to dosing should be used
only in patients who match the demographic and clinical char-
acteristics of the enrolled cohort. Therefore, it cannot be used
for patients requiring different types of renal replacement ther-
apies and should be used with caution in obese patients and
those with low creatinine clearances. Finally, the simulations
suggest more aggressive doses than those that are typically
prescribed, and therefore, any prospective validation study
would need to closely monitor for potential vancomycin toxic-
ities to confirm that these are not increased in frequency by this
approach to dosing.
In conclusion, dose optimization of vancomycin by CI can be
best accomplished using a rational approach that considers
individual patient and disease characteristics. Specifically,
TBW should be considered for initial dosing, as it is an accu-
rate descriptor of volume of distribution of vancomycin. Main-
tenance dosing can then be guided by CrCl. Such an approach
to administration of vancomycin by CI can increase the likeli-
hood of achieving therapeutic concentrations and reduce the
possibility of subtherapeutic drug exposure. Recommended
loading and daily doses would result in insufficient drug con-
centrations during the early phase of sepsis, and higher doses
should be used in this setting. We would advocate that a clin-
ical study be undertaken to validate the findings of these sim-
ulations.
ACKNOWLEDGMENT
J.A.R. is funded by Australian Based Health Professional Research
Fellowship 569917.
REFERENCES
1. Bauer, L. A., D. J. Black, and J. S. Lill. 1998. Vancomycin dosing in morbidly
obese patients. Eur. J. Clin. Pharmacol. 54:621–625.
2. Beal, S. L., and L. B. Sheiner. 1998. NONMEM user guides (I-VIII). Uni-
versity of California at San Francisco, San Francisco, CA.
3. Blot, S. I., K. H. Vandewoude, E. A. Hoste, and F. A. Colardyn. 2002.
Outcome and attributable mortality in critically ill patients with bacteremia
involving methicillin-susceptible and methicillin-resistant Staphylococcus au-
reus. Arch. Intern. Med. 162:2229–2235.
4. Burton, D. C., J. R. Edwards, T. C. Horan, J. A. Jernigan, and S. K. Fridkin.
2009. Methicillin-resistant Staphylococcus aureus central line-associated
bloodstream infections in US intensive care units, 1997–2007. JAMA 301:
727–736.
5. De Backer, D., et al. 2010. Comparison of dopamine and norepinephrine in
the treatment of shock. N. Engl. J. Med. 362:779–789.
6. del Mar Fernandez de Gatta Garcia, M., N. Revilla, M. V. Calvo, A. Domin-
guez-Gil, and A. Sanchez Navarro. 2007. Pharmacokinetic/pharmacody-
namic analysis of vancomycin in ICU patients. Intensive Care Med. 33:279–
285.
7. DeRyke, C. A., and D. P. Alexander. 2009. Optimizing vancomycin dosing
through pharmacodynamic assessment targeting area under the concentra-
tion-time curve/minimum inhibitory concentration. Hosp. Pharm. 44:751–
756.
8. Drusano, G. L. 2004. Antimicrobial pharmacodynamics: critical interactions
of ‘bug and drug’. Nat. Rev. Microbiol. 2:289–300.
9. Finfer, S., et al. 2004. Adult-population incidence of severe sepsis in Aus-
tralian and New Zealand intensive care units. Intensive Care Med. 30:589–
596.
10. Garnacho-Montero, J., et al. 2003. Impact of adequate empirical antibiotic
therapy on the outcome of patients admitted to the intensive care unit with
sepsis. Crit. Care Med. 31:2742–2751.
11. Giuliano, C., K. K. Haase, and R. Hall. 2010. Use of vancomycin pharma-
cokinetic-pharmacodynamic properties in the treatment of MRSA infec-
tions. Expert Rev. Anti Infect. Ther. 8:95–106.
12. Hardy, K. J., P. M. Hawkey, F. Gao, and B. A. Oppenheim. 2004. Methicillin
resistant Staphylococcus aureus in the critically ill. Br. J. Anaesth. 92:121–
130.
13. Ho, K. M., and J. O. Robinson. 2009. Risk factors and outcomes of methi-
cillin-resistant Staphylococcus aureus bacteraemia in critically ill patients: a
case control study. Anaesth. Intensive Care 37:457–463.
14. Jeffres, M. N., et al. 2006. Predictors of mortality for methicillin-resistant
Staphylococcus aureus health-care-associated pneumonia. Chest 130:947–
955.
15. Jeurissen, A., I. Sluyts, and R. Rutsaert. 2011. A higher dose of vancomycin
in continuous infusion is needed in critically ill patients. Int. J. Antimicrob.
Agents 37:75–77.
16. Knaus, W. A., E. A. Draper, D. P. Wagner, and J. E. Zimmerman. 1985.
APACHE II: a severity of disease classification system. Crit. Care Med.
13:818–829.
17. Kollef, M. H., G. Sherman, S. Ward, and V. J. Fraser. 1999. Inadequate
antimicrobial treatment of infections: a risk factor for hospital mortality
among critically ill patients. Chest 115:462–474.
18. Kumar, A., et al. 2006. Duration of hypotension before initiation of effective
antimicrobial therapy is the critical determinant of survival in human septic
shock. Crit. Care Med. 34:1589–1596.
19. Llopis-Salvia, P., and N. V. Jimenez-Torres. 2006. Population pharmacoki-
netic parameters of vancomycin in critically ill patients. J. Clin. Pharm. Ther.
31:447–454.
20. Marik, P. E. 1993. Aminoglycoside volume of distribution and illness severity
in critically ill septic patients. Anaesth. Intensive Care 21:172–173.
21. Matthews, I., C. Kirkpatrick, and N. Holford. 2004. Quantitative justification
for target concentration intervention-parameter variability and predictive
performance using population pharmacokinetic models for aminoglycosides.
Br. J. Clin. Pharmacol. 58:8–19.
22. Moise-Broder, P. A., A. Forrest, M. C. Birmingham, and J. J. Schentag.
2004. Pharmacodynamics of vancomycin and other antimicrobials in patients
with Staphylococcus aureus lower respiratory tract infections. Clin. Pharma-
cokinet. 43:925–942.
23. Parke, J., N. H. Holford, and B. G. Charles. 1999. A procedure for gener-
ating bootstrap samples for the validation of nonlinear mixed-effects popu-
lation models. Comput. Methods Programs Biomed. 59:19–29.
24. Pea, F., et al. 2009. Prospectively validated dosing nomograms for maximis-
ing the pharmacodynamics of vancomycin administered by continuous infu-
sion in critically ill patients. Antimicrob. Agents Chemother. 53:1863–1867.
25. Pea, F., L. Porreca, M. Baraldo, and M. Furlanut. 2000. High vancomycin
dosage regimens required by intensive care unit patients cotreated with
FIG. 4. The effect of different doses (mg/kg) on vancomycin con-
centrations administered by continuous infusion after a 35-mg/kg
loading dose in a patient with a creatinine clearance of 100 ml/min/
1.73 m2.
2708 ROBERTS ET AL. ANTIMICROB. AGENTS CHEMOTHER.
 o
n
 N
ovem
ber 4, 2015 by University of Queensland Library
http://aac.asm
.org/
D
ow
nloaded from
 
drugs to improve haemodynamics following cardiac surgical procedures. J.
Antimicrob. Chemother. 45:329–335.
26. Potoski, B. A., and D. L. Paterson. 2007. Appropriate pharmacokinetic index
for outcome in Staphylococcus aureus pneumonia. Chest 132:1101–1103.
27. Roberts, J. A., and J. Lipman. 2009. Pharmacokinetic issues for antibiotics in
the critically ill patient. Crit. Care Med. 37:840–851.
28. Rybak, M., et al. 2009. Therapeutic monitoring of vancomycin in adult
patients: a consensus review of the American Society of Health-System
Pharmacists, the Infectious Diseases Society of America, and the Society of
Infectious Diseases Pharmacists. Am. J. Health Syst. Pharm. 66:82–98.
29. Rybak, M. J. 2006. The pharmacokinetic and pharmacodynamic properties
of vancomycin. Clin. Infect. Dis. 42(Suppl. 1):S35–S39.
30. Rybak, M. J., et al. 2009. Vancomycin therapeutic guidelines: a summary of
consensus recommendations from the Infectious Diseases Society of Amer-
ica, the American Society of Health-System Pharmacists, and the Society of
Infectious Diseases Pharmacists. Clin. Infect. Dis. 49:325–327.
31. Udy, A. A., J. A. Roberts, R. J. Boots, D. L. Paterson, and J. Lipman. 2010.
Augmented renal clearance: implications for antibacterial dosing in the
critically ill. Clin. Pharmacokinet. 49:1–16.
32. Vincent, J. L., et al. 1998. Use of the SOFA score to assess the incidence of
organ dysfunction/failure in intensive care units: results of a multicenter,
prospective study. Working group on “sepsis-related problems” of the Eu-
ropean Society of Intensive Care Medicine. Crit. Care Med. 26:1793–1800.
33. Wysocki, M., et al. 2001. Continuous versus intermittent infusion of vanco-
mycin in severe staphylococcal infections: prospective multicenter random-
ized study. Antimicrob. Agents Chemother. 45:2460–2467.
VOL. 55, 2011 VANCOMYCIN BY CONTINUOUS INFUSION IN ICU PATIENTS 2709
 o
n
 N
ovem
ber 4, 2015 by University of Queensland Library
http://aac.asm
.org/
D
ow
nloaded from
 
